我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
6
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
FDA
Food and Drug Administration
- Gensco Pharma has acquired global rights and intellectual property for RizaFilm and RizaPort, innovative oral dissolvable film treatments for migraines already approved by FDA and EMA. - The company plans to launch RizaFilm in the U.S. market by Q4 2025 while pursuing international expansion in Asia, the Middle East, and the Americas through licensing partnerships. - The acquisition positions Gensco strategically in the multi-billion-dollar migraine treatment market, addressing unmet patient needs with a water-free administration method for faster relief.
